Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06914895 · ClinicalTrials.gov registry record · Phase 3

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
905
Enrollment target
20
Study locations

NCT06914895 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 905 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06914895, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
905 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

Conditions Studied

Obesity Overweight Type 1 Diabetes

Interventions

  • DRUG Placebo
  • DRUG Tirzepatide

Study Locations (20)

Georgia

  • Atlanta Diabetes Associates - Atlanta
  • Orita Clinical Research - Decatur
  • North Georgia Clinical Research - Woodstock

New York

  • Albany Medical College, Division of Community Endocrinology - Albany
  • Research Foundation of SUNY - University of Buffalo - Buffalo
  • NYC Research - New York

California

  • Sansum Diabetes Research Institute - Santa Barbara
  • Care Access - Santa Clarita - Santa Clarita

Nevada

  • Palm Research Center Tenaya - Las Vegas
  • Palm Research Center Sunset - Las Vegas

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Hawaii

  • East-West Medical Research Institute - Honolulu

Idaho

  • Rocky Mountain Clinical Research - Idaho Falls

Illinois

  • Southern Illinois University School of Medicine - Springfield

Trial Details

FieldValue
Enrollment Target 905 participants
Start Date 2025-04-25
Est. Completion 2026-12
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06914895

The ClinicalTrials.gov registry entry for NCT06914895 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (11% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06914895 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Georgia, New York, California.

Frequently Asked Questions

What is clinical trial NCT06914895 about?

NCT06914895 is a clinical study titled "A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight". The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.

What is the current status of trial NCT06914895?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 905 participants. The study started on 2025-04-25. Estimated completion is 2026-12.

What conditions does trial NCT06914895 study?

This clinical trial studies the following conditions: Obesity, Overweight, Type 1 Diabetes.

What interventions are being tested in trial NCT06914895?

The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).

Who is sponsoring clinical trial NCT06914895?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06914895 being conducted?

This trial has 20 study locations across California, Colorado, Georgia, Hawaii, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.